Similarly, animals treated with the PPARδ agonist GW501516 exhibited an accelerated formation of breast cancer tumors, particularly adenosquamous and squamous cell carcinomas, and tumors of mice treated with GW501516 exhibited increased levels of PPARδ and activated PDK1 (Yin et al., 2005). Here, PDK1 is linked to breast cancer.